Clinical Research Directory
Browse clinical research sites, groups, and studies.
Gabapentin and Pressor Response to Intubation
Sponsor: Liaquat National Hospital & Medical College
Summary
This study evaluates the effectiveness of oral gabapentin in reducing the pressor response (increased MAP, HR, and BP) during laryngoscopic intubation. It is a prospective, double-blind randomized controlled trial involving 144 patients undergoing elective surgery. Gabapentin 300 mg or placebo will be administered preoperatively, with hemodynamic parameters monitored before and after intubation. The study aims to determine if gabapentin attenuates the sympathetic stress response compared to placebo.
Official title: GABAPENTIN ATTENUATES THE PRESSOR RESPONSE TO DIRECT LARYNGOSCOPY AND TRACHEAL INTUBATION
Key Details
Gender
All
Age Range
18 Years - 59 Years
Study Type
INTERVENTIONAL
Enrollment
144
Start Date
2024-12-15
Completion Date
2025-07-16
Last Updated
2024-11-26
Healthy Volunteers
No
Conditions
Interventions
Gabapentin Group (Group G): Patients will receive 300 mg of oral Gabapentin
In this study, the intervention involves administering 300 mg of oral gabapentin to patients in the intervention group two hours prior to surgery, aiming to assess its efficacy in attenuating the pressor response to laryngoscopy and tracheal intubation.
Placebo Oral Tablet
The placebo group will receive an identical capsule without active medication, administered two hours before surgery, to compare its effects with those of gabapentin on the pressor response to laryngoscopy and tracheal intubation.